AbbVie Expects 9% Tax Rate, Thanks To US Tax Reform Law
Executive Summary
The tax reform windfall makes an already strong fourth quarter and full year 2017 financial report more impressive for AbbVie, which reported continuing growth for Humira and Imbruvica, and a big uptick in HCV.
You may also be interested in...
How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says
As pharma invests its bounty from last year's tax reform in stock buybacks, capital improvements and other investments, Sen. Cory Booker issues a report suggesting companies should lower drug prices instead, but does not offer recommendations for how that might be done.
Pharma Q4 Results Preview: Bristol, Allergan, Gilead, GSK, Sanofi, Teva
Hemophilia and immuno-oncology will be in the spotlight as earnings season continues into February. Will Bristol be a buyer or an acquisition target? How will Sanofi fare with its new acquisitions? And how will Teva and GSK fare as they face generics for top brands?
J&J Shows Grace Under Pressure From Biosimilars And Other Threats
Oncology stars Darzalex and Imbruvica lift a strong fourth quarter, but Remicade biosimilars and pricing discounts continue to threaten to take a bite out of future performance. Tax reform and Amazon's potential entry into healthcare could also affect the diversified firm.